Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Contributed by: Business Wire

Logo

Tags

Health

Other Consumer

Consumer

Women

Other Health

Pharmaceutical

Biotechnology

Organon & Co.

More Like This

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Organon to Present New Research on Access and Value at ISPOR 2026

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

PR Newswire associated0

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis